ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimer's Association International Conference (AAIC-2017)
BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - July 24, 2017) - Excellent safety data profile on 106 healthy volunteers The molecule is brain penetrant Data allows establishment of a safe administration scheme for long term efficacy studies Oryzon …